{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:39:06Z","timestamp":1774535946658,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.vaccine.2017.05.004","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T23:47:12Z","timestamp":1494373632000},"page":"3318-3325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice"],"prefix":"10.1016","volume":"35","author":[{"given":"Weiping","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Hyang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian J.","family":"Reber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Hoelscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Belser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivaprakash","family":"Gangappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Plante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Burt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suryaprakash","family":"Sambhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.05.004_b0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/CMR.05012-11","article-title":"Two years after pandemic influenza A\/2009\/H1N1: what have we learned?","volume":"25","author":"Cheng","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.05.004_b0010","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(97)11212-0","article-title":"Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus","volume":"351","author":"Claas","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.05.004_b0015","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/erv.12.25","article-title":"Microneedle and mucosal delivery of influenza vaccines","volume":"11","author":"Kang","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.05.004_b0020","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1586\/erv.12.31","article-title":"Mucosal immunity and nasal influenza vaccination","volume":"11","author":"Rose","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.05.004_b0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/clin.1995.1019","article-title":"Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies","volume":"74","author":"Shalaby","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2017.05.004_b0030","doi-asserted-by":"crossref","first-page":"e1001397","DOI":"10.1371\/journal.pbio.1001397","article-title":"Inside the mucosal immune system","volume":"10","author":"McGhee","year":"2012","journal-title":"PLoS Biol"},{"key":"10.1016\/j.vaccine.2017.05.004_b0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0169-409X(01)00162-4","article-title":"Nasal vaccines","volume":"51","author":"Davis","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2017.05.004_b0040","first-page":"181","article-title":"Live attenuated influenza vaccine","volume":"vol. II","author":"Jin","year":"2014"},{"key":"10.1016\/j.vaccine.2017.05.004_b0045","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.vaccine.2004.09.010","article-title":"A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice","volume":"23","author":"Chabot","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.004_b0050","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.1016\/j.vaccine.2007.06.017","article-title":"Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice","volume":"25","author":"Hu","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.004_b0055","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1016\/j.vaccine.2007.01.037","article-title":"C57Bl\/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine","volume":"25","author":"Cyr","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.004_b0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcv.2009.01.009","article-title":"Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine","volume":"44","author":"Huang","year":"2009","journal-title":"J Clin Virol: Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.vaccine.2017.05.004_b0065","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.vaccine.2005.09.052","article-title":"Intranasal Protollin\/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection","volume":"24","author":"Jones","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.004_b0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1128\/CVI.05441-11","article-title":"Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A\/H3N2 influenza vaccines in mice","volume":"19","author":"Baz","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.05.004_b0075","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1126\/science.1236194","article-title":"Research funding. A framework for decisions about research with HPAI H5N1 viruses","volume":"339","author":"Patterson","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.05.004_b0080","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/erv.10.172","article-title":"Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations","volume":"10","author":"Burt","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.05.004_b0085","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2017.05.004_b0090","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.vaccine.2005.07.088","article-title":"Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects","volume":"24","author":"Treanor","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.004_b0095","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.vaccine.2005.09.056","article-title":"Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults","volume":"24","author":"Langley","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.004_b0100","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.vaccine.2010.12.100","article-title":"A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness","volume":"29","author":"Langley","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.004_b0105","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.1016\/j.vaccine.2014.08.029","article-title":"Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines","volume":"32","author":"Ann","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.004_b0110","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1073\/pnas.1115369109","article-title":"Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection","volume":"109","author":"Onodera","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.05.004_b0115","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/eji.1830140414","article-title":"Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity","volume":"14","author":"Liew","year":"1984","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2017.05.004_b0120","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1046\/j.1365-3083.1998.00435.x","article-title":"Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship","volume":"48","author":"Paludan","year":"1998","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2017.05.004_b0125","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/383787a0","article-title":"Functional diversity of helper T lymphocytes","volume":"383","author":"Abbas","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.05.004_b0130","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1146\/annurev.immunol.15.1.749","article-title":"Cellular responses to interferon-gamma","volume":"15","author":"Boehm","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.05.004_b0135","doi-asserted-by":"crossref","first-page":"R201","DOI":"10.1186\/cc8208","article-title":"Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza","volume":"13","author":"Bermejo-Martin","year":"2009","journal-title":"Crit Care"},{"key":"10.1016\/j.vaccine.2017.05.004_b0140","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.4049\/jimmunol.0900657","article-title":"IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge","volume":"182","author":"McKinstry","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.05.004_b0145","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1186\/cc10426","article-title":"Imbalanced pro- and anti-Th17 responses (IL-17\/granulocyte colony-stimulating factor) predict fatal outcome in 2009 pandemic influenza","volume":"15","author":"Almansa","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.vaccine.2017.05.004_b0150","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.4049\/jimmunol.1200645","article-title":"The development and function of memory regulatory T cells after acute viral infections","volume":"189","author":"Sanchez","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.05.004_b0155","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4161\/hv.21117","article-title":"The regulatory T cells in anti-influenza antibody response post influenza vaccination","volume":"8","author":"Wang","year":"2012","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2017.05.004_b0160","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nm.1929","article-title":"Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10","volume":"15","author":"Sun","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2017.05.004_b0165","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.vaccine.2008.10.073","article-title":"TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model","volume":"27","author":"Cyr","year":"2009","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1730600X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1730600X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T01:50:26Z","timestamp":1535853026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1730600X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":33,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0264410X1730600X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.004","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}